Traws Pharma Reports Positive Phase 2 Ratutrelvir Data for COVID-19 and Expands Tivoxavir Marboxil Program for Influenza Prophylaxis
TRAW has more than doubled off its 52-week low of $0.97 on light trading volume (0.2× avg).
Summary
Traws Pharma announced the completion of enrollment and positive preliminary results for its Phase 2 COVID-19 study of ratutrelvir, while also revealing plans to develop tivoxavir marboxil as a prophylactic treatment for seasonal influenza.
Key Events · Product Development and Regulatory · TRAW
-
Ratutrelvir Phase 2 Enrollment Complete
Traws Pharma completed enrollment in its 90-patient, open-label Phase 2 study of ratutrelvir for mild-to-moderate COVID-19, including a arm for PAXLOVID-ineligible patients.
-
Positive Preliminary Ratutrelvir Data
Ongoing data analysis confirms ratutrelvir's differentiated profile with fewer adverse events, no viral rebounds to date, and faster time to sustained symptom resolution, including in PAXLOVID-ineligible patients.
-
Tivoxavir Marboxil Expanded Indication
The company is progressing tivoxavir marboxil (TXM) as a single monthly oral tablet for the prophylactic treatment of seasonal influenza, aiming for 28-day protection.
-
Influenza Challenge Study Secured
A human influenza prophylaxis challenge study time slot has been secured for June 2026 to advance TXM into registration studies.
Analysis · TRAW · Life Sciences
This filing provides significant positive updates on Traws Pharma's lead antiviral programs. The completion of enrollment and preliminary positive data for ratutrelvir in a Phase 2 COVID-19 study, particularly its differentiated profile and efficacy in PAXLOVID-ineligible patients, suggests a strong potential for this candidate. Concurrently, the expansion of tivoxavir marboxil into a prophylactic treatment for seasonal influenza, with a secured challenge study, opens a new and substantial market opportunity. For a clinical-stage biopharmaceutical company of this size, these advancements represent critical value inflection points, potentially de-risking its pipeline and expanding its addressable markets.
At the time of this filing, TRAW was trading at $2.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.3M. The 52-week trading range was $0.97 to $8.61. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.